Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Myers Squibb Company

https://www.bms.com/

Latest From Bristol Myers Squibb Company

Sawai Urges Japan To Take 'Best And Only Chance' To Reform Pricing Amid Generic Crisis

Kenzo Sawai, president of Japanese generics giant Sawai Pharmaceutical, tells Scrip in the first of a two-part exclusive interview about the firm’s strategy and backstory of efforts to maintain product supplies amid the country’s ongoing generic crisis. He also urges Japan to take "the best and only chance" to reform its drug pricing system to help the entire market survive.

Japan Generic Drugs

AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting

Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.

Clinical Trials Business Strategies

Sanofi’s MS Candidate Tolebrutinib On Clinical Hold Following Liver Toxicities

The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.

Clinical Trials Companies

Novartis’s Latecomer PD-1 Outshines Keytruda And Opdivo In Esophageal Cancer

Novartis is playing catch-up in PD-1 inhibitors but could soon claim a best-in-class competitor in first-line esophageal cancer.

Clinical Trials Companies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Abraxis BioScience, Inc.
    • AbVitro, Inc.
    • Acetylon Pharmaceuticals, Inc.
    • Adnexus Therapeutics, Inc.
    • Allied-Bristol Life Sciences, LLC
    • Amira Pharmaceuticals, Inc.
    • Amylin Pharmaceuticals, Inc.
    • Avila Therapeutics, Inc.
    • Bristol-Myers Company
    • Bristol-Myers K.K.
    • Bristol-Myers Squibb
    • Cardioxyl Pharmaceuticals
    • Celgene Corporation
    • Cormorant Pharmaceuticals
    • Delinia, Inc.
    • EngMab AG
    • Flexus Biosciences, Inc.
    • Gloucester Pharmaceuticals, Inc.
    • ißeCa Therapeutics
    • IFM Therapeutics
    • Impact Biomedicines, Inc.
    • Inhibitex, Inc.
    • iPierian Inc.
    • Juno Therapeutics, Inc.
    • Juno Therapeutics GmbH (Stage Cell Therapeutics GmbH)
    • JW Biotechnology (Shanghai) Co., Ltd
    • Kosan
    • Medarex, Inc.
    • Padlock Therapeutics, Inc.
    • Pharmion Corporation
    • Quanticel Pharmaceuticals, Inc.
    • Receptos, Inc.
    • RedoxTherapies, Inc.
    • Westwood-Squibb Pharmaceuticals
    • X-BODY, Inc.
    • ZymoGenetics, Inc.
    • Forbius
    • MyoKardia Inc.
UsernamePublicRestriction

Register